What is the female-to-male ratio for primary pulmonary arterial hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Female-to-Male Ratio in Primary PAH

The female-to-male ratio for idiopathic (primary) pulmonary arterial hypertension is 1.7:1 1, 2.

Epidemiologic Data

The most authoritative data comes from the ACCF/AHA 2009 Expert Consensus Document, which clearly states that idiopathic PAH (IPAH) has a female/male ratio of 1.7:1 with a mean age at diagnosis of 37 years 1. This ratio was confirmed by the National Institutes of Health registry data from 187 patients, which documented the same 1.7:1 female predominance 2.

Important Context and Variations

While the overall ratio for IPAH is 1.7:1, the female predominance varies significantly depending on the specific PAH subtype and associated conditions:

Broader PAH Categories:

  • General pulmonary hypertension (all types): 1.8:1 female-to-male ratio 3
  • Pulmonary arterial hypertension subtype specifically: Up to 4:1 female predominance 4, 5, 6
  • Adult PAH (broader definition): 2:1 to 4:1 female-to-male ratio 7

Associated PAH Conditions:

  • Connective tissue disease-associated PAH: Dramatically skewed at 9:1 female-to-male ratio 8
  • Hereditary PAH with BMPR2 mutations: Shows incomplete penetrance with female predominance only after puberty, suggesting hormonal influence 7

Clinical Significance

The female predominance is paradoxical because despite higher incidence in women, they demonstrate:

  • Better baseline right ventricular function 9, 10
  • Superior hemodynamic indices (higher PA pulsatility index and RV stroke work index) 9
  • Better response to endothelin receptor antagonists and prostacyclins 10
  • Lower mortality risk compared to men (adjusted HR 0.60) 11

This "estrogen paradox" suggests that while female sex hormones may increase susceptibility to developing PAH, they may simultaneously provide protective effects on RV adaptation and overall survival 12.

Key Caveat

The age of PAH patients has been increasing over time. While the original NIH registry from 1981 showed a mean age of 36 years, current registries show mean ages between 50-65 years, and the female predominance may not be present in elderly patients 3. This temporal shift emphasizes that the 1.7:1 ratio represents the classic presentation but may not fully capture contemporary epidemiology in older populations.

References

Research

The Role of Sex in the Pathophysiology of Pulmonary Hypertension.

Advances in experimental medicine and biology, 2018

Research

Pulmonary arterial hypertension: sex-specific differences and outcomes.

Therapeutic advances in respiratory disease, 2025

Research

The estrogen paradox in pulmonary arterial hypertension.

American journal of physiology. Lung cellular and molecular physiology, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.